CN108148126A - A kind of people C21ORF13 polypeptides and its preparation method for antibody - Google Patents
A kind of people C21ORF13 polypeptides and its preparation method for antibody Download PDFInfo
- Publication number
- CN108148126A CN108148126A CN201611143852.1A CN201611143852A CN108148126A CN 108148126 A CN108148126 A CN 108148126A CN 201611143852 A CN201611143852 A CN 201611143852A CN 108148126 A CN108148126 A CN 108148126A
- Authority
- CN
- China
- Prior art keywords
- c21orf13
- antibody
- terminal
- people
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 51
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 38
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 10
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 9
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 7
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 7
- 210000002966 serum Anatomy 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 238000004132 cross linking Methods 0.000 claims description 8
- 238000002649 immunization Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000001261 affinity purification Methods 0.000 claims description 6
- 230000003053 immunization Effects 0.000 claims description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 230000001804 emulsifying effect Effects 0.000 claims description 2
- 108091005601 modified peptides Proteins 0.000 claims 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 2
- 101710153593 Albumin A Proteins 0.000 claims 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 claims 1
- 229940098773 bovine serum albumin Drugs 0.000 claims 1
- 239000000568 immunological adjuvant Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000003119 immunoblot Methods 0.000 abstract description 6
- 238000004458 analytical method Methods 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 4
- 238000011091 antibody purification Methods 0.000 abstract description 3
- 230000000890 antigenic effect Effects 0.000 abstract description 3
- 238000012512 characterization method Methods 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract 1
- 238000003364 immunohistochemistry Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 201000010374 Down Syndrome Diseases 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- RPLLQZBOVIVGMX-QWRGUYRKSA-N Gly-Asp-Phe Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RPLLQZBOVIVGMX-QWRGUYRKSA-N 0.000 description 1
- NQCJGQHHYZNUDK-DCAQKATOSA-N Lys-Arg-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CCCN=C(N)N NQCJGQHHYZNUDK-DCAQKATOSA-N 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- FCRMLGJMPXCAHD-FXQIFTODSA-N Ser-Arg-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O FCRMLGJMPXCAHD-FXQIFTODSA-N 0.000 description 1
- 208000037280 Trisomy Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses the preparation methods of a kind of special people C21ORF13 polypeptides of N-terminal and antibody, belong to the biological products of the experiment in vitro characterized by antibody.The amino acid sequence of the special people's C21ORF13 polypeptides of N-terminal is：KRSPGTGDFSRNSN.Anti-human C21ORF13 polypeptide antibodies are prepared as follows：(1) people C21ORF13 Characterization of antigenic epitopes；(2) people C21ORF13 N-terminals Peptide systhesis；(3) synthesis polypeptide is crosslinked with carrier protein；(4) rabbit-anti people's C21ORF13 polypeptide antibodies are prepared；(5) it collects, the isolated serum containing antibody, antibody purification is to get to anti-human C21ORF13 polypeptide antibodies.The anti-human C21ORF13 synthesis of polypeptide antibody potency of N-terminal prepared by the present invention specifically is high, affinity is strong, specificity is good, can occur to specifically bind with natural human C21ORF13 and react；Manufacturing cost is low；Antibody after purification can be used for immunoblotting and immunohistochemistry.Basic research of the antibody for C21ORF13 albumen, such as the characteristic to C21ORF13, function, express spectra and the analysis of content and its research of relevant disease provide an important tool.
Description
1. technical field
The present invention relates to a kind of polypeptide and its preparation method for antibody, this antibody is mainly used for the inspection of native protein antigen
It surveys.
2. background technology
1) C21ORF13 functions：Down syndromes (Down Syndrome), also known as 21- Trisomies (21trisomy
Syndrome) or mongolism, it is a kind of most common clinical hereditary metabolic disorders, the incidence in life birth baby is
0.12-0.16%.Cytogenetic Features are in three signs for No. 21 chromosome, are occurred mainly since reproduction cell is subtracting
With the period of the day from 11 p.m. to 1 a.m or fertilized eggs, No. 21 chromosomes generations in mitosis do not detach for speed division formation, and embryoid body is made to exist into the cell
One No. 21 additional chromosome.Primary Study finds that the overexpression of C21ORF13 albumen is considered additional with this 21
Number chromosome is related, and therefore, the further investigation to C21ORF13 albumen, to the pathogenesis of the disease, clinical classification is precisely treated
And prevention has important impetus.(PLoS One.2016Apr21；11(4)).
2) C21ORF13 antibody products information：Through retrieval, there is the polyclonal antibody of C21ORF13 albumen in the market, but this
The epitope of a little antibody is different with the epitope of my company.
3) application of C21ORF13 antibody：Primary Study discovery, excessive table of the C21ORF13 albumen in Down syndromes
Up to the exercising result for being this additional No. 21 chromosome.This suggests that us, which is possible to the generation in the disease, develops
Cheng Zhong plays an important role, be likely to become soon in the future one it is potential with basic research and clinical value
Therefore disease marker, researches and develops polypeptide corresponding with its target protein and its specific antibody, will be to studying the albumen and its at this
Disease occurs, the effect in evolution, and epigenetics and clinic precisely treatment and prevention provide accurate reliably tool and material
Material, is of great significance.
3. invention content
The present invention provides a kind of C21ORF13 polypeptides, sequence is：KRSPGTGDFSRNSN.It is prepared with this polypeptide anti-
C21ORF13 antibody can be natural in specific recognition tissue or cell in immunoblotting (Western blot) analysis
C21ORF13 albumen.
Anti- C21ORF13 antibody through the following steps that obtain：
Step 1：The analysis and design of peptide sequence：Using DNAstar softwares to the amino acid sequence of C21ORF13 albumen
Progress Characterization of antigenic epitopes, mainly assesses hydrophily, antigenicity, surface possibility, and the indexes such as flex region were prepared in conjunction with the past
The practical experience of antibody, finally determining C21ORF13-43 14 amino acid of protein 29 are as synthesis polypeptide amino acid sequence, sequence
It is classified as KRSPGTGDFSRNSN.
Step 2：Peptide systhesis and crosslinking：Desired polypeptides are synthesized using ACT396 fully-automatic multi-channels Peptide synthesizer, and
It is identified using mass spectrum；To enhance the antigenicity of polypeptide, KRSPGTGDFSRNSN polypeptides and carrier protein KLH are used
Sulfo-SMCC cross-linking methods are crosslinked.
Step 3：It is prepared by polypeptide immune and antiserum：By the C21ORF13-KLH after crosslinking and Freund's adjuvant mixing and emulsifying,
Intradermal injection immunity, and booster immunization repeatedly are carried out at new zealand rabbit back, is stopped until blood examination is taken to survey when antibody titer reaches standard
Only it is immunized.
Step 4：Antibody purification：After experimental rabbit antibody titer reaches standard, using heart extracting blood, antiserum is detached, is used
After Protein A purifying whole antibodies, further using peptide affinity purification, target antibody is obtained.
Anti- C21ORF13 antibody through the following steps that identification：
Step 1：Immunoblotting：Using the C21ORF13 antibody obtained as primary antibody, using the immunoblotting side of standard
Method, confirm the antibody can with the natural C21ORF13 protein-interactings after denaturation, available for western blot test.
4. description of the drawings
Fig. 1 is western blot figure (Western blot)
5. specific embodiment
1. the analysis and design of peptide sequence
Characterization of antigenic epitopes, main assessment parent are carried out to the amino acid sequence of C21ORF13 albumen using DNAstar softwares
Aqueous, antigenicity, surface possibility, the indexes such as flex region prepared the practical experience of antibody in conjunction with the past, consider amino acid knot
Structure complexity, oxidizable degree synthesize difficulty, and amino acid classification and distribution etc. finally determine C21ORF13 protein 29s -43
14 amino acid are as synthesis polypeptide amino acid sequence, sequence KRSPGTGDFSRNSN.Meanwhile to ensure the crosslinking of later stage polypeptide
Carrier protein and peptide affinity purification increase a cysteine C in N-terminal, and final peptide sequence to be synthesized is C-
KRSPGTGDFSRNSN。
2. Peptide systhesis and crosslinking
Using ACT396 fully-automatic multi-channel Peptide synthesizers, desired polypeptides are automatically synthesized according to the program woven, it will
Polypeptide after synthesis is dissolved in 50% acetonitrile, is identified using mass spectrograph, and it is purpose polypeptide to confirm obtained polypeptide.Using
Carrier protein KLH is crosslinked by Sulfo-SMCC as crosslinking agent with synthesis polypeptide：10mg KLH is taken to be dissolved in 0.5ml ultra-pure waters
In；3mg sulfo-SMCC is taken to be dissolved in 0.5ml ultra-pure waters, with 3MNaOH tune pH value 7 or so.In mixing,
Sulfo-SMCC solution is slowly added to dropwise in KLH solution, rotates mixing reactant 30min at room temperature.It will be completely reacted
Sulfo-SMCC/KLH mixed liquors are loaded in advance with equilibration buffer (0.05M PB, pH6.0) equilibrated 30min's
In Sephadex G25 columns, light grey eluent, that is, the sulfo-SMCC/KLH solution activated are collected.With 200ul PBS
(pH7.3) 2mg cross linking polypeptides are treated in dissolving, and the sulfo-SMCC/KLH complex solutions of 0.2 volume are added in polypeptide solution,
Adjusting pH value, rocked at room temperature 4 hours is spare after being lyophilized 24 hours with freeze dryer after -70 DEG C of freezings to 7.3.It is examined by Ellman methods
Polypeptide sulfydryl determines polypeptide cross-linking efficiency before and after test cross connection.
3. prepared by polypeptide immune and antiserum
The 400 μ g of KLH- polypeptides being crosslinked are dissolved in 400 μ l phosphate buffers (0.01M PBS), are added in equal volume not
Family name's Freund's complete adjuvant is fully emulsified (to indiffusion in water).Using 3 months rabbit ages, the health of weight 1.75-2.25Kg was new
Western blue rabbit is immunized, and is carried out back intradermal injection immunity, at least to be injected 20 points or more.After first immunisation 3 weeks, by 300 μ g
Polypeptide is dissolved in 300 μ l phosphate buffers (0.01M PBS), intradermal with the fully emulsified rear progress of the incomplete Freund's adjuvant of equivalent
It is immune, as first time booster immunization, it is desirable that back intradermal injection immunity will at least inject 15 points or more.Second 3 weeks immune
Afterwards, second of booster immunization is carried out, method and requirement are the same as first time booster immunization.After 1 week, blood is taken using auricular vein is micro,
With uncrosslinked synthesis polypeptide coated elisa plate, indirect elisa method detection immune serum potency.It repeats booster immunization and potency is surveyed
Fixed, until serum titer reaches more than 1: 60000, using heart extracting blood, standard method obtains antiserum.
4. antibody affinity purification
(1), TIgG is purified：50% Protein-A Sepharose suspensions 10ml is added to 30ml layers with pipettor
It analyses in column, removes top lid and bottom cap, the bed volume after liquid outflow is 5ml, is then rinsed 3 times with 25ml deionized waters.
Corresponding serum 10ml is taken out, is added in 30ml chromatographic columns after being mixed with 2ml PBS, room temperature (20-25 DEG C) on impeller
Mixed 1 hour, allows blood serum sample to flow out.Purify washing lotion with 15ml again and wash chromatographic column 3 times, add in 10ml eluents and eluted.
(2), peptide affinity purification：1ml Sulfo-link gel suspensions (0.5ml gels) are added in chromatographic column, are treated in column
Dried liquid stream rinses chromatographic column with 4ml coupling buffers.The C21ORF13 polypeptides synthesized with the dissolving of 1ml coupling buffers, and add
Enter chromatographic column, add in 1ml coupling buffers to chromatographic column, room temperature overturns mixing 1 hour.It is rinsed with 6ml coupling buffers
Then chromatographic column adds in 3ml confining liquids, room temperature mixing 1 hour.It rinses chromatographic column 3 times, 6ml [gG is then added in into chromatographic column
And 3ml PBS, room temperature overturn mixing 1 hour.Chromatographic column is rinsed with PBS 3 times, then with 2ml elutions.By what is obtained
Antibody purification is packed into 4 DEG C of dialysis in bag filter.Dialysed overnight, then 4000rpm × 35min centrifugations collect supernatant except precipitation.With
Indirect elisa method measures antibody titer and measures protein concentration with Bradford methods.
Anti- C21ORF13 antibody through the following steps that identification：
1. immunoblotting assay
PAGE gel is prepared according to standard method, by the cell or Tissue Lysis that 5 μ l protein concentrations are 5mg/ml
Liquid is loaded successively, constant pressure 80V about 30 minutes, when sample ran concentration matrix sheet in straight line, changes 160V voltages, electrophoresis
Electrophoresis is terminated when running out of separation gel (about 60 minutes) completely to bromophenol blue indicator, turns 80 using electric transferring film method constant pressure 100V electricity
Minute transferring film is to pvdf membrane.
Using the C21ORF13 antibody obtained as primary antibody, the antigen core obtained using a concentration of 1 μ l/ml and above-mentioned transferring film
Piece hybridizes 1 hour at room temperature, is then hybridized at room temperature 1 hour with the HRP goat anti-rabbit antibodies marked, using ECL development processes
It develops the color, is developed the color and exposed with X pieces in darkroom, obtain immunoblot results.
Polypeptid acid sequence table
Lys Arg Ser Pro Gly Thr Gly Asp Phe Ser Arg Asn Ser Asn.
Claims (6)
1. a kind of people C21ORF13 polypeptides, it is characterised in that the amino acid sequence of polypeptide is：KRSPGTGDFSRNSN.
A kind of 2. preparation method for antibody of anti-human C21ORF13 polypeptides, it is characterised in that the sequent synthesis N-terminal as described in claim 1
The N-terminal modified peptides of synthesis and carrier protein are crosslinked, animal are immunized with crosslinked peptide, the blood of immune animal is taken to prepare by modified peptides
Antiserum isolates and purifies IgG from serum, wherein the N-terminal is modified to the N-terminal one and half Guang ammonia of increase in amino acid sequence
Sour residue.
3. preparation method for antibody according to claim 2, it is characterised in that carrier protein for keyhole limpet hemocyanin (KLH) or
Bovine serum albumin(BSA) (BSA).
4. preparation method for antibody according to claim 2, it is characterised in that N-terminal modified peptides by crosslinking agent by its sulfydryl with
Carrier protein amino covalence is crosslinked.
5. preparation method for antibody according to claim 2, it is characterised in that after crosslinking peptide and immunologic adjuvant mixing and emulsifying,
Rabbit back is subcutaneously injected by multiple spot, and through secondary Yi Shang booster immunization, and the potency of serum is more than 1: 10000.
6. preparation method for antibody according to claim 2, it is characterised in that by ammonium sulfate precipitation, albumin A affinity purification
And peptide affinity purification can obtain the IgG of high-purity from antiserum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611143852.1A CN108148126A (en) | 2016-12-05 | 2016-12-05 | A kind of people C21ORF13 polypeptides and its preparation method for antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611143852.1A CN108148126A (en) | 2016-12-05 | 2016-12-05 | A kind of people C21ORF13 polypeptides and its preparation method for antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108148126A true CN108148126A (en) | 2018-06-12 |
Family
ID=62467734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611143852.1A Withdrawn CN108148126A (en) | 2016-12-05 | 2016-12-05 | A kind of people C21ORF13 polypeptides and its preparation method for antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108148126A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114437210A (en) * | 2022-02-25 | 2022-05-06 | 海南浙江大学研究院 | Polypeptide for preparing anti-rice AGO16 protein antibody, preparation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105985422A (en) * | 2015-01-30 | 2016-10-05 | 天津奥维亚生物技术有限公司 | Human SH3BGR polypeptide and preparation method for antibody thereof |
| CN106167792A (en) * | 2015-05-18 | 2016-11-30 | 天津奥维亚生物技术有限公司 | A kind of people's SARDH polypeptide and preparation method for antibody thereof |
-
2016
- 2016-12-05 CN CN201611143852.1A patent/CN108148126A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105985422A (en) * | 2015-01-30 | 2016-10-05 | 天津奥维亚生物技术有限公司 | Human SH3BGR polypeptide and preparation method for antibody thereof |
| CN106167792A (en) * | 2015-05-18 | 2016-11-30 | 天津奥维亚生物技术有限公司 | A kind of people's SARDH polypeptide and preparation method for antibody thereof |
Non-Patent Citations (2)
| Title |
|---|
| ANONYMOUS: "CAB90455.1", 《GENBANK》 * |
| CLAIRE SPELLMAN ET AL: "Expression of trisomic proteins in Down syndrome model systems", 《GENE》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114437210A (en) * | 2022-02-25 | 2022-05-06 | 海南浙江大学研究院 | Polypeptide for preparing anti-rice AGO16 protein antibody, preparation method and application |
| CN114437210B (en) * | 2022-02-25 | 2023-11-07 | 海南浙江大学研究院 | Polypeptide for preparing rice AGO16 protein antibody, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105585636B (en) | Human NOTCH1NICD protein Ser2162 site phosphorylation antibody and preparation method and application thereof | |
| CN102633864B (en) | GPC3 antigen polypeptide, anti-GPC3 polyclonal antibody and application thereof | |
| RU2009143671A (en) | HIGH-SENSITIVE IMMUNO ANALYSIS AND KITS FOR DETERMINING PEPTIDES AND PROTEINS OF INTEREST | |
| CN103360468B (en) | Preparation method for SCD1 polypeptide and anti-goose SCD1 polypeptide polyclonal antibody | |
| CN110272502B (en) | Immunogen, hybridoma cell secreting anti-cardiac troponin I monoclonal antibody, preparation method, monoclonal antibody and application | |
| CN112114150A (en) | Method and product for diagnosing seafood allergy | |
| CN105985422A (en) | Human SH3BGR polypeptide and preparation method for antibody thereof | |
| CN110317270A (en) | Antitoxin snake PLA2Protein antibodies and its application | |
| CN101880316B (en) | A kind of human RBPMS polypeptide and its antibody preparation method | |
| CN109627306B (en) | Antigen epitope of rice grain glutenin GluA2 subunit, its antibody and application | |
| CN108148127A (en) | A kind of people MAP3K7IP2 polypeptides and its preparation method for antibody | |
| Johansson et al. | Development of monoclonal antibodies for detection of antisecretory factor activity in human plasma | |
| CN108148124A (en) | A kind of Human HNRPA 0 polypeptide and its preparation method for antibody | |
| CN108148126A (en) | A kind of people C21ORF13 polypeptides and its preparation method for antibody | |
| CN102336814B (en) | Polypeptide sequence for preparing anti-liver-neoplasm marker CK-19 antibody, polyclonal antibody and application thereof | |
| JP4318458B2 (en) | pan-specific monoclonal antibody | |
| CN101928332A (en) | Preparation method of Human HNRPA0 polypeptide and antibody thereof | |
| CN103113455B (en) | Preparation and application of hemagglutinin peptide mark recombinant protein immunoaffinity purification enriching column | |
| CN101928334B (en) | Preparation method of mouse Ehf polypeptide and antibody thereof | |
| CN108148125A (en) | A kind of human EIF 4 H polypeptide and its preparation method for antibody | |
| CN108117592A (en) | A kind of people ZNF294 polypeptides and its preparation method for antibody | |
| WO2018074533A1 (en) | Immunoassay method using anti-human bnp fragment (4-32) antibody | |
| CN104311654A (en) | CIDE3 polypeptide, preparation of antibody thereof and applications of the antibody | |
| CN108117593A (en) | A kind of people ZNF295 polypeptides and its preparation method for antibody | |
| CN113832132A (en) | Solder tip SVMP protein specific short peptide, solder tip SVMP protein antibody and snake bite detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180612 |
|
| WW01 | Invention patent application withdrawn after publication |